Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathryn E Beckermann

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Oncogene|March 4, 2020
Modeling clear cell renal cell carcinoma and therapeutic implicationsMelissa M Wolf, W Kimryn Rathmell, Kathryn E Beckermann
Oncology (Williston Park, N.Y.)|April 24, 2018
Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune DiseaseDouglas B Johnson, Kathryn E Beckermann, Daniel Y Wang
Cancers|October 14, 2022
Emerging Targets in Clear Cell Renal Cell CarcinomaYu-Wei Chen, Brian I Rini, Kathryn E Beckermann
Expert Review of Clinical Immunology|July 19, 2016
PD-1/PD-L1 blockade in renal cell cancerKathryn E Beckermann, Douglas B Johnson, Jeffrey A Sosman
Cytokine & Growth Factor Reviews|May 1, 2017
Dysfunctional T cell metabolism in the tumor microenvironmentKathryn E Beckermann, Stephanie O Dudzinski, Jeffrey C Rathmell
Expert Opinion on Biological Therapy|April 23, 2021
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapySelina K Wong, Kathryn E Beckermann, Douglas B Johnson, et al.
Urologic Oncology|January 17, 2017
Strategies to overcome therapeutic resistance in renal cell carcinomaPeter J Siska, Kathryn E Beckermann, W Kimryn Rathmell, et al.
JAMA Oncology|March 27, 2025
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma: A ReviewGiulia Claire Giudice, Kathryn E Beckermann, Paulo Siqueira Do Amaral, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2023
Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?Catherine C Fahey, Jeffrey W Shevach, Ronan Flippot, et al.
Frontiers in Oncology|January 8, 2021
Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case ReportsMatthew D Tucker, Kathryn E Beckermann, Jennifer B Gordetsky, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Oncogene|March 4, 2020
Modeling clear cell renal cell carcinoma and therapeutic implicationsMelissa M Wolf, W Kimryn Rathmell, Kathryn E Beckermann
Oncology (Williston Park, N.Y.)|April 24, 2018
Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune DiseaseDouglas B Johnson, Kathryn E Beckermann, Daniel Y Wang
Cancers|October 14, 2022
Emerging Targets in Clear Cell Renal Cell CarcinomaYu-Wei Chen, Brian I Rini, Kathryn E Beckermann
Expert Review of Clinical Immunology|July 19, 2016
PD-1/PD-L1 blockade in renal cell cancerKathryn E Beckermann, Douglas B Johnson, Jeffrey A Sosman
Cytokine & Growth Factor Reviews|May 1, 2017
Dysfunctional T cell metabolism in the tumor microenvironmentKathryn E Beckermann, Stephanie O Dudzinski, Jeffrey C Rathmell
Expert Opinion on Biological Therapy|April 23, 2021
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapySelina K Wong, Kathryn E Beckermann, Douglas B Johnson, et al.
Urologic Oncology|January 17, 2017
Strategies to overcome therapeutic resistance in renal cell carcinomaPeter J Siska, Kathryn E Beckermann, W Kimryn Rathmell, et al.
JAMA Oncology|March 27, 2025
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma: A ReviewGiulia Claire Giudice, Kathryn E Beckermann, Paulo Siqueira Do Amaral, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2023
Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?Catherine C Fahey, Jeffrey W Shevach, Ronan Flippot, et al.
Frontiers in Oncology|January 8, 2021
Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case ReportsMatthew D Tucker, Kathryn E Beckermann, Jennifer B Gordetsky, et al.
Pageof 6